Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
AIDS
    April 2024
  1. FRESSE A, Massy N, Fournier D, Pinel S, et al
    Adverse drug reaction profile of third-generation smallpox vaccines used in France during the 2022 monkeypox epidemic.
    AIDS. 2024;38:768-771.
    >> Share

    March 2024
  2. GIANELLA S, Anderson C, Chaillon A, Wells A, et al
    Impact of influenza and pneumococcal vaccines on HIV persistence and immune dynamics during suppressive antiretroviral therapy.
    AIDS. 2024 Mar 25. doi: 10.1097/QAD.0000000000003882.
    >> Share

    February 2024
  3. DAUBY N, Gagneux-Brunon A, Martin C, Mussi-Pinhata MM, et al
    Maternal immunization in women living with HIV.
    AIDS. 2024;38:137-144.
    >> Share

    January 2024
  4. DUNCAN MC, Omondi FH, Kinloch NN, Lapointe HR, et al
    Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
    AIDS. 2024 Jan 15. doi: 10.1097/QAD.0000000000003841.
    >> Share

  5. BLAZKOVA J, Shi V, Manning MR, Kennedy BD, et al
    Effect of influenza vaccination on the persistence of HIV reservoirs and immunologic parameters in people with HIV.
    AIDS. 2024;38:131-133.
    >> Share

  6. VOLKOW P, Islas-Munoz B, Carpio-Guadarrama D, Perez-Padilla R, et al
    Exacerbation of Kaposi sarcoma after MVA-BN (Jynneos) vaccination in a person with HIV/AIDS.
    AIDS. 2024;38:129-130.
    >> Share

    December 2023
  7. KEBEDE S, Brazier E, Freeman AM, Muwonge TR, et al
    PrEP Availability Among Health Facilities Participating in the Global IeDEA Consortium.
    AIDS. 2023 Dec 22. doi: 10.1097/QAD.0000000000003824.
    >> Share

  8. JACOBSON JM, Felber BK, Chen H, Pavlakis GN, et al
    The immunogenicity of an HIV-1 gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy.
    AIDS. 2023 Dec 4. doi: 10.1097/QAD.0000000000003804.
    >> Share

    November 2023
  9. KAUR G, Perry RT
    Preventing measles in children and adolescents with HIV.
    AIDS. 2023;37:2087-2089.
    >> Share

    October 2023
  10. CHAMMARTIN F, Griessbach A, Kusejko K, Audige A, et al
    Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1.
    AIDS. 2023 Oct 12. doi: 10.1097/QAD.0000000000003751.
    >> Share

    September 2023
  11. NUNES MC, Tamblyn A, Jose L, Ntsimane M, et al
    Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003731.
    >> Share

  12. RACCAGNI AR, Diotallevi S, Lolatto R, Lucente MF, et al
    Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003733.
    >> Share

    August 2023
  13. MOTTA E, Camacho LAB, Cunha M, de Filippis AB, et al
    Immunogenicity and reactogenicity of yellow fever vaccine in people living with HIV.
    AIDS. 2023 Aug 24. doi: 10.1097/QAD.0000000000003696.
    >> Share

  14. COSTINIUK CT, Singer J, Lee T, Galipeau Y, et al
    Antibody neutralization capacity after COVID-19 vaccination in people with HIV (CIHR Canadian HIV trials network 328).
    AIDS. 2023 Aug 3. doi: 10.1097/QAD.0000000000003680.
    >> Share

  15. AHMAD A, Samarani S, Costiniuk CT
    Antibody and T-cell responses elicited by coronavirus disease 2019 vaccination in people with HIV-1: the case of late presenters.
    AIDS. 2023;37:1625-1627.
    >> Share

    June 2023
  16. MUTEMBO S, Yang Y, Carcelen A, Winter AK, et al
    Measles immunity gaps among children and adolescents with HIV in zambia despite high measles vaccination and antiretroviral therapy coverage.
    AIDS. 2023 Jun 29. doi: 10.1097/QAD.0000000000003634.
    >> Share

  17. SHUBIN Z, Stanfield-Oakley S, Puangkaew J, Pitisutthithum P, et al
    Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector functions magnitude but not durability.
    AIDS. 2023 Jun 1. doi: 10.1097/QAD.0000000000003611.
    >> Share

    May 2023
  18. AUGELLO M, Bono V, Rovito R, Tincati C, et al
    Six-month immune responses to mRNA-1273 Vaccine in cART-treated late presenter people living with HIV according to previous SARS-CoV-2 Infection.
    AIDS. 2023 May 5. doi: 10.1097/QAD.0000000000003585.
    >> Share

    April 2023
  19. GRIFFIN DW, Pai Mangalore R, Hoy JF, Mcmahon JH, et al
    Immunogenicity, effectiveness and safety of SARS-CoV-2 vaccination in people living with HIV: A systematic review and meta-analysis.
    AIDS. 2023 Apr 14. doi: 10.1097/QAD.0000000000003579.
    >> Share

  20. VON TOKARSKI F, Fourn E, Faucheron A, Chan Hew Wai A, et al
    Smallpox vaccine acceptability among French men having sex with men living with HIV in settings of monkeypox outbreak.
    AIDS. 2023;37:855-856.
    >> Share

  21. SU B, Vanham G
    Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals.
    AIDS. 2023;37:837-839.
    >> Share

    March 2023
  22. WILCK M, Barnabas S, Chokephaibulkit K, Violari A, et al
    A phase 3 study of safety and immunogenicity of V114, a 15-valent PCV, followed by PPSV23, in children living with HIV.
    AIDS. 2023 Mar 20. doi: 10.1097/QAD.0000000000003551.
    >> Share


  23. COVID-19 vaccine immunogenicity in people with HIV: Erratum.
    AIDS. 2023;37:559.
    >> Share

    February 2023
  24. CHEUNG PK, Lapointe HR, Sang Y, Ennis S, et al
    SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive ART.
    AIDS. 2023 Feb 14. doi: 10.1097/QAD.0000000000003519.
    >> Share

  25. CASADO JL, Vizcarra P, Martin-Colmenarejo S, Del Pino J, et al
    Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people living with HIV.
    AIDS. 2023 Feb 8. doi: 10.1097/QAD.0000000000003504.
    >> Share

  26. SOOKAROMDEE P, Wiwanitkit V
    Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people with HIV.
    AIDS. 2023;37:365-366.
    >> Share

  27. MARTIN C, Domingo C, Hainaut M, Delforge M, et al
    Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection.
    AIDS. 2023;37:341-346.
    >> Share

    January 2023
  28. MAUAS R, Urena A, Cecchini D, Strada ML, et al
    Adverse events and SARS-CoV-2 antibody responses after immunization with sputnik V, ChAdOx1-S and BBIBP-CorV vaccines in people with HIV.
    AIDS. 2023 Jan 16. doi: 10.1097/QAD.0000000000003483.
    >> Share

  29. MCMAHON WC, Kwatra G, Izu A, Koen AL, et al
    T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
    AIDS. 2023;37:105-112.
    >> Share

  30. COSTINIUK CT, Singer J, Lee T, Langlois MA, et al
    COVID-19 vaccine immunogenicity in people with HIV.
    AIDS. 2023;37:F1-F10.
    >> Share

    December 2022
  31. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
    Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART.
    AIDS. 2022 Dec 23. doi: 10.1097/QAD.0000000000003469.
    >> Share

    October 2022
  32. CHAMBERS C, Samji H, Cooper CL, Costiniuk CT, et al
    COVID-19 Vaccine Effectiveness among a Population-based Cohort of People Living with HIV.
    AIDS. 2022 Oct 19. pii: 00002030-990000000-00126.
    >> Share

  33. WONG NS, Wong BCK, Chan JMC, Wong KH, et al
    Humoral responses to coronavirus disease 2019 vaccines in people with HIV: authors' reply.
    AIDS. 2022;36:1747-1748.
    >> Share

  34. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Surrogate neutralization responses following SARS-CoV-2 vaccination in people with HIV.
    AIDS. 2022;36:1746-1747.
    >> Share

    August 2022
  35. THINDWA D, Mwalukomo TS, Msefula J, Jambo KC, et al
    Risk factors for pneumococcal carriage in adults living with HIV on antiretroviral therapy in the infant pneumococcal vaccine era in Malawi.
    AIDS. 2022 Aug 22. pii: 00002030-990000000-00094.
    >> Share

  36. CHAMMARTIN F, Kusejko K, Pasin C, Trkola A, et al
    Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
    AIDS. 2022;36:1465-1468.
    >> Share

    July 2022
  37. GIANSERRA L, Dona MG, Giuliani E, Stingone C, et al
    High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
    AIDS. 2022;36:1319-1320.
    >> Share

  38. WOLDEMESKEL BA, Karaba AH, Garliss CC, Beck EJ, et al
    Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.
    AIDS. 2022;36:1315-1317.
    >> Share

  39. CRUM NF, Ahmad A
    Immunity against measles in people with HIV: the need for more research and surveillance.
    AIDS. 2022;36:1305-1306.
    >> Share

    June 2022
  40. POURCHER V, Belin L, Soulie C, Rosenzwajg M, et al
    High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2.
    AIDS. 2022 Jun 23. pii: 00002030-990000000-00043.
    >> Share

    April 2022
  41. WONG NS, Wong BCK, Chan JMC, Wong KH, et al
    Surrogate neutralisation responses following SARS-CoV-2 vaccination in people living with HIV - comparison between inactivated and mRNA vaccine.
    AIDS. 2022 Apr 23. pii: 00002030-990000000-00010.
    >> Share

    March 2022
  42. LEFEBVRE M, Secher S, Bouchez S, Vandamme YM, et al
    Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination.
    AIDS. 2022 Mar 8. pii: 00002030-990000000-00002.
    >> Share

  43. XU X, Vesterbacka J, Aleman S, Nowak P, et al
    High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
    AIDS. 2022;36:479-481.
    >> Share

    February 2022
  44. DURIER C, Mercier-Delarue S, Verdiere NC, Meiffredy V, et al
    A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults.
    AIDS. 2022;36:319-321.
    >> Share

  45. SHAVER ZM, Anderson M, Bhebhe L, Baruti K, et al
    Decreased HBV vaccine response among HIV positive infants compared to HIV negative infants in Botswana.
    AIDS. 2022 Feb 1. pii: 00002030-900000000-96228.
    >> Share

    January 2022
  46. HASSOLD N, Brichler S, Ouedraogo E, Leclerc D, et al
    Impaired antibody response to COVID-19 vaccination in advanced HIV infection.
    AIDS. 2022 Jan 10. pii: 00002030-900000000-96241.
    >> Share

  47. ALEDO MG, Canizares A, Vazquez-Rodriguez P, Castro A, et al
    Safety and immunogenicity of SARS-CoV-2 mRNA-1273 and BNT162b2 vaccines in people living with HIV.
    AIDS. 2022 Jan 6. pii: 00002030-900000000-96246.
    >> Share

    December 2021
  48. SPINELLI MA, Brown LB, Glidden DV, Hunter K, et al
    SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV.
    AIDS. 2021;35:2545-2547.
    >> Share

    November 2021
  49. MOHAPI L, Pinedo Y, Osiyemi O, Supparatpinyo K, et al
    Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study.
    AIDS. 2021 Nov 8. pii: 00002030-900000000-96271.
    >> Share

    August 2021
  50. MARASINI B, Vyas HK, Lakhashe SK, Hariraju D, et al
    Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection.
    AIDS. 2021 Aug 16. pii: 00002030-900000000-96332.
    >> Share

    June 2021
  51. LIU G, Mugo NR, Brown ER, Mgodi NM, et al
    Prevalent HPV infection increases the risk of HIV acquisition in African women: advancing the argument for HPV immunization.
    AIDS. 2021 Jun 24. pii: 00002030-900000000-96360.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016